| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5621 | 2021 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... The Lancet 396 (10249), 467-478, 2020 | 2896 | 2020 |
| Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1761 | 2020 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1402 | 2021 |
| ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques N Van Doremalen, T Lambe, A Spencer, S Belij-Rammerstorfer, ... Nature 586 (7830), 578-582, 2020 | 1186 | 2020 |
| A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity MDJ Dicks, AJ Spencer, NJ Edwards, G Wadell, K Bojang, SC Gilbert, ... PloS one 7 (7), e40385, 2012 | 425 | 2012 |
| Preliminary assessment of the efficacy of a t-cell–based influenza vaccine, MVA-NP+ M1, in humans PJ Lillie, TK Berthoud, TJ Powell, T Lambe, C Mullarkey, AJ Spencer, ... Clinical infectious diseases 55 (1), 19-25, 2012 | 297 | 2012 |
| Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) A Flaxman, NG Marchevsky, D Jenkin, J Aboagye, PK Aley, B Angus, ... The Lancet 398 (10304), 981-990, 2021 | 284 | 2021 |
| A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys AD Douglas, GC Baldeviano, CM Lucas, LA Lugo-Roman, C Crosnier, ... Cell host & microbe 17 (1), 130-139, 2015 | 265 | 2015 |
| Viral vectors as vaccine platforms: from immunogenicity to impact KJ Ewer, T Lambe, CS Rollier, AJ Spencer, AVS Hill, L Dorrell Current opinion in immunology 41, 47-54, 2016 | 233 | 2016 |
| Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors SH Sheehy, CJA Duncan, SC Elias, KA Collins, KJ Ewer, AJ Spencer, ... Molecular Therapy 19 (12), 2269-2276, 2011 | 207 | 2011 |
| Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors SH Sheehy, CJA Duncan, SC Elias, S Biswas, KA Collins, GA O'Hara, ... PloS one 7 (2), e31208, 2012 | 199 | 2012 |
| Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass R Alcock, MG Cottingham, CS Rollier, J Furze, SD De Costa, M Hanlon, ... Science translational medicine 2 (19), 19ra12-19ra12, 2010 | 183 | 2010 |
| Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19 SP Graham, RK McLean, AJ Spencer, S Belij-Rammerstorfer, D Wright, ... NPJ vaccines 5 (1), 69, 2020 | 155 | 2020 |
| AT cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+ M1 in adults aged over 50 years RD Antrobus, PJ Lillie, TK Berthoud, AJ Spencer, JE McLaren, K Ladell, ... PloS one 7 (10), e48322, 2012 | 146 | 2012 |
| Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice AJ Spencer, PF McKay, S Belij-Rammerstorfer, M Ulaszewska, CD Bissett, ... Nature communications 12 (1), 2893, 2021 | 133 | 2021 |
| Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA) MG Cottingham, RF Andersen, AJ Spencer, S Saurya, J Furze, AVS Hill, ... PloS one 3 (2), e1638, 2008 | 120 | 2008 |
| Optimising Controlled Human Malaria Infection Studies Using Cryopreserved P. falciparum Parasites Administered by Needle and Syringe SH Sheehy, AJ Spencer, AD Douglas, BKL Sim, RJ Longley, NJ Edwards, ... PloS one 8 (6), e65960, 2013 | 117 | 2013 |
| MAIT cell activation augments adenovirus vector vaccine immunogenicity NM Provine, A Amini, LC Garner, AJ Spencer, C Dold, C Hutchings, ... Science 371 (6528), 521-526, 2021 | 109 | 2021 |
| Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME … C Ogwang, M Afolabi, D Kimani, YJ Jagne, SH Sheehy, CM Bliss, ... PloS one 8 (3), e57726, 2013 | 104 | 2013 |